Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Operating Leases: 2023-2025

Historic Operating Leases for China SXT Pharmaceuticals (SXTC) over the last 3 years, with Mar 2025 value amounting to $176,648.

  • China SXT Pharmaceuticals' Operating Leases fell 53.38% to $85,161 in Q3 2025 from the same period last year, while for Sep 2025 it was $85,161, marking a year-over-year decrease of 53.38%. This contributed to the annual value of $176,648 for FY2025, which is 25.10% down from last year.
  • Latest data reveals that China SXT Pharmaceuticals reported Operating Leases of $176,648 as of FY2025, which was down 25.10% from $235,848 recorded in FY2024.
  • In the past 5 years, China SXT Pharmaceuticals' Operating Leases registered a high of $306,050 during FY2023, and its lowest value of $176,648 during FY2025.
  • Its 3-year average for Operating Leases is $239,515, with a median of $235,848 in 2024.
  • Data for China SXT Pharmaceuticals' Operating Leases shows a maximum YoY declined of 25.10% (in 2025) over the last 5 years.
  • Yearly analysis of 3 years shows China SXT Pharmaceuticals' Operating Leases stood at $306,050 in 2023, then declined by 22.94% to $235,848 in 2024, then fell by 25.10% to $176,648 in 2025.